Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bipolar I Disorder Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

ERG Components in Schizophrenia and Bipolar Disorder Type I

NCT03788811
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
ERG assessment (RSPA)
Device
Lead sponsor
diaMentis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
11
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181727
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510
View directory record Official record
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 7:26 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

NCT01677182
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Anaheim, California • Glendale, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER

NCT00211250
View directory record Official record
Conditions
Mood Disorder
Interventions
Valproic Acid and Depakote ER
Drug
Lead sponsor
Joliet Center for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

NCT01059539
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Springdale, Arkansas • Carson, California • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder

NCT00178061
View directory record Official record
Conditions
Bipolar I Disorder, Borderline Personality Disorder
Interventions
Interpersonal Social Rhythm Therapy (IPSRT)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

NCT01567527
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517
View directory record Official record
Conditions
Seasonal Affective Disorder, Mood Disorders, Depression
Interventions
bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 20, 2026, 7:26 PM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate Bipolar Maintenance Monotherapy

NCT00314184
View directory record Official record
Conditions
Bipolar Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
30
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 20, 2026, 7:26 PM EDT
Recruiting Phase 4 Interventional

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

NCT05648591
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Dothan, Alabama • Little Rock, Arkansas • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine for Mania

NCT01058096
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Long Beach, California • Riverside, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 20, 2026, 7:26 PM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

NCT03854409
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Little Rock, Arkansas • Garden Grove, California • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 20, 2026, 7:26 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy Study of Lithium in Bipolar Disorder

NCT00422331
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
Lithium Carbonate Capsule
Drug
Lead sponsor
JDS Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Oct 20, 2026, 7:26 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

NCT00363337
View directory record Official record
Conditions
Bipolar Depression
Interventions
aripiprazole
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 20, 2026, 7:26 PM EDT
Withdrawn Phase 2 Interventional

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

NCT01981811
View directory record Official record
Conditions
Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions
Aripiprazole, Ingestible Event Marker (IEM)
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Cerritos, California • Garden Grove, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 20, 2026, 7:26 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
OLZ/SAM, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Dothan, Alabama • Little Rock, Arkansas • Encino, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder

NCT01126827
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 20, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

NCT00094549
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, divalproex sodium, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Costa Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 20, 2026, 7:26 PM EDT